Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Orvepitant. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 known ✓ | P25103 | 19/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 1.00 |
| ▸ | PTAFR | P25105 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Orvepitant SCHEMBL21931158 | 1.00 | TACR1 (1.00) | TACR1SIGMAR1PTAFRCYP3A4 | |
| Orvepitant SCHEMBL2483270 | 1.00 | TACR1 (1.00) | TACR1SIGMAR1PTAFRCYP3A4 | |
| Orvepitant SCHEMBL29373789 | 1.00 | TACR1 (1.00) | TACR1SIGMAR1PTAFRCYP3A4 | |
| Orvepitant SCHEMBL2484579 | 1.00 | TACR1 (1.00) | TACR1SIGMAR1PTAFRCYP3A4 | |
| Orvepitant SCHEMBL19581227 | 1.00 | TACR1 (1.00) | TACR1SIGMAR1PTAFRCYP3A4 | |
| Orvepitant SCHEMBL23895405 | 1.00 | TACR1 (1.00) | TACR1SIGMAR1PTAFRCYP3A4 | |
| Orvepitant SCHEMBL19117640 | 1.00 | TACR1 (1.00) | TACR1SIGMAR1PTAFRCYP3A4 | |
| Orvepitant SCHEMBL2179896 | 1.00 | TACR1 (1.00) | TACR1SIGMAR1PTAFRCYP3A4 | |
| Orvepitant SCHEMBL5360752 | 0.99 | TACR1 (0.99) | TACR1SIGMAR1PTAFRCYP3A4 | |
| Orvepitant SCHEMBL30110395 | 0.99 | TACR1 (0.99) | TACR1SIGMAR1PTAFRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1615641-A1 | COMBINATIONS OF PAROXETINE AND 2-(R)-(4-FLUORO-2-METHYL-PHENYL)-4-(S)-((8AS)-6-OXO-HEXAHYDRO-PYRROLO 1,2-A -PYRAZIN-2-YL)-PIPERIDINE-1-CARBOXYLIC ACID 1-(R)-(3,5-BIS-TRIFLUOROMETHYL-PHENYL)-ETHYL -METHYLAMIDE FOR TREATMENT OF DEPRESSION/ANXIETY | GLAXO GROUP LIMITED (GB) | 2006-01-18 | — | — | EP | claimed |
| WO-2004091615-A1 | COMBINATIONS OF PAROXETINE AND 2-(R)-(4-FLUORO-2-METHYL-PHENYL)-4-(S)-((8AS)-6-OXO-HEXAHYDRO-PYRROLO[1,2-A]-PYRAZIN-2-YL)-PIPERIDINE-1-CARBOXYLIC ACID[1-(R)-(3,5-BIS-TRIFLUOROMETHYL-PHENYL)-ETHYL]-METHYLAMIDE FOR TREATMENT OF DEPRESSION/ANXIETY | GLAXO GROUP LIMITED (GB) | 2004-10-28 | — | — | WO | claimed |
| WO-2026090360-A1 | FUSED PYRIMIDINE COMPOUNDS FOR TREATMENT OF TINNITUS, HEARING LOSS, AND MENIERE'S DISEASE | OVID THERAPEUTICS INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20260108529-A1 | FUSED AMINO PYRIMIDINE COMPOUNDS FOR TREATMENT OF TINNITUS, ACUTE SENSORINEURAL HEARING LOSS, AGE-RELATED HEARING LOSS, AND MENIERE'S DISEASE | OVID THERAPEUTICS INC (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4426280-B1 | PROTECTION AGAINST ARTHROPOD PARASITES WITH PURINERGIC RECEPTOR (OPR) ANTAGONISTS | GURBA ALEXANDRE (CH) | 2026-03-18 | — | — | EP | disclosed |
| US-20250302821-A1 | SYNERGISTIC ANTIFUNGAL COMPOSITION AND METHOD | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. | 2025-10-02 | — | — | US | disclosed |
| US-20250195459-A1 | USE OF (1S,3S)-3-AMINO-4-(DIFLUOROMETHYLIDENE) CYCLOPENTANE-1-CARBOXYLIC ACID AND (S)-3-AMINO-4-(DIFLUOROMETHYLENYL)CYCLOPENT-1-ENE-1-CARBOXYLIC ACID IN THE TREATMENT OF TINNITUS, ACUTE SENSORINEURAL HEARING LOSS, MENIERE’S DISEASE, TOURETTE’S SYNDROME, ATTENTION DEFICIT HYPERACTIVITY DISORDER AND ADDICTION | OVID THERAPEUTICS INC. | 2025-06-19 | — | — | US | disclosed |
| US-20250057791-A1 | PROTECTION AGAINST ARTHROPOD PARASITES WITH PURINERGIC RECEPTOR (OPR) ANTAGONISTS | GURBA ALEXANDRE (CH) | 2025-02-20 | — | — | US | disclosed |
| EP-4461362-A2 | NK1-ANTAGONIST COMBINATION AND METHOD FOR TREATING SYNUCLEINOPATHIES | Chase Therapeutics Corporation (US) | 2024-11-13 | — | — | EP | disclosed |
| EP-4426280-A1 | PROTECTION AGAINST ARTHROPOD PARASITES WITH PURINERGIC RECEPTOR (OPR) ANTAGONISTS | Gurba, Alexandre (CH) | 2024-09-11 | — | — | EP | disclosed |
| CN-115427033-B | NK-1 receptor antagonists for the treatment of diseases selected from sepsis, septic shock, acute Respiratory Distress Syndrome (ARDS) or Multiple Organ Dysfunction Syndrome (MODS) | 尼尔医疗有限公司 | 2024-08-09 | — | — | CN | disclosed |
| EP-2297152-A1 | ANHYDROUS CRYSTAL FORM OF ORVEPITANT MALEATE | Glaxo Group Limited (GB) | 2011-03-23 | — | — | EP | disclosed |
| WO-2009124996-A1 | ANHYDROUS CRYSTAL FORM OF ORVEPITANT MALEATE | GLAXO GROUP LIMITED (GB) | 2009-10-15 | — | — | WO | disclosed |
| WO-2009124996-A1 | ANHYDROUS CRYSTAL FORM OF ORVEPITANT MALEATE | GLAXO GROUP LIMITED (GB) | 2009-10-15 | — | — | WO | disclosed |
| EP-1041449-B1 | Electrophotographic image-forming method, electrophotographic image-forming apparatus, and process cartridge | CANON KK (JP) | 2004-10-13 | — | — | EP | disclosed |
| US-6384099-B1 | APPLYING DENTAL MATERIAL INCLUDING MONOMERS AND INITIATOR SENSITIVE TO LIGHT OF PARTICULAR WAVELENGTH TO DENTAL SURFACE, EXPOSING MATERIAL TO LIGHT AT FIRST POWER LEVEL TO INITIATE POLYMERIZATION, EXPOSING TO LIGHT AT SECOND POWER LEVEL | LASER MED. INC. | 2002-05-07 | — | — | US | disclosed |
| US-6282013-B1 | System for curing polymeric materials, such as those used in dentistry, and for tailoring the post-cure properties of polymeric materials through the use of light source power modulation | LASERMED, INC. | 2001-08-28 | — | — | US | disclosed |
| US-6215971-B1 | Electrophotographic image-forming method, electrophotographic image-forming apparatus, and process cartridge | CANON KABUSHIKI KAISHA (JP) | 2001-04-10 | — | — | US | disclosed |
| EP-1041449-A1 | Electrophotographic image-forming method, electrophotographic image-forming apparatus, and process cartridge | CANON KABUSHIKI KAISHA (JP) | 2000-10-04 | — | — | EP | disclosed |
| US-6008264-A | APPLYING A DENTAL MATERIAL WITH LIGHT SENSITIVE INITIATOR TO A DENTAL SURFACE, EXPOSING TO LIGHT SOURCE AT FIRST POWER LEVEL TO INITIATE POLYMERIZATION, SIMULTANEOUSLY DECREASING LEVEL OF LIGHT, MAINTAINING UNTIL MATERIAL IS POLYMERIZED | LASER MED, INC. (US) | 1999-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250195459-A1 | USE OF (1S,3S)-3-AMINO-4-(DIFLUOROMETHYLIDENE) CYCLOPENTANE-1-CARBOXYLIC ACID AND (S)-3-AMINO-4-(DIFLUOROMETHYLENYL)CYCLOPENT-1-ENE-1-CARBOXYLIC ACID IN THE TREATMENT OF TINNITUS, ACUTE SENSORINEURAL HEARING LOSS, MENIERE’S DISEASE, TOURETTE’S SYNDROME, ATTENTION DEFICIT HYPERACTIVITY DISORDER AND ADDICTION | SLC6A3, SLC1A2, SLC1A3 | TACR1 659/4885SIGMAR1 2610/4885PTAFR 746/4885 |
| US-20260108529-A1 | FUSED AMINO PYRIMIDINE COMPOUNDS FOR TREATMENT OF TINNITUS, ACUTE SENSORINEURAL HEARING LOSS, AGE-RELATED HEARING LOSS, AND MENIERE'S DISEASE | OTC, MEN1, MT-CO1 | TACR1 3463/4885SIGMAR1 4461/4885PTAFR 1986/4885 |
| US-20250057791-A1 | PROTECTION AGAINST ARTHROPOD PARASITES WITH PURINERGIC RECEPTOR (OPR) ANTAGONISTS | P2RX2, P2RX3, P2RX1 | TACR1 34/4885SIGMAR1 257/4885PTAFR 222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.